Varifarma signs an exclusive distribution and license agreement with Recordati for Ledaga® in Argentina. Basel (Switzerland) and Buenos Aires (Argentina) January 25th, 2021 – Laboratorio Varifarma SA, a company focused on complex therapies and orphan diseases, and devoted to increasing the life expectancy of the patient announce they have signed an exclusive distribution and licensing agreement for Ledaga® in Argentina with Recordati AG, Rare Diseases branch, a pharmaceutical company committed to providing often overlooked orphan therapies to the underserved rare disease communities in the World. Ledaga® (chlormethine hydrochloride) is a novel gel formulation, applied once a day, indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL), a rare disease characterized by the abnormal accumulation of malignant T-cells in the skin. MFCTCL is the most common type of cutaneous lymphoma and first presents as patches and plaques on the skin. It is difficult to diagnose, particularly in the early stages as many of its features are non-specific. Chlormethine is an alkylating agent that inhibits quickly proliferating cells and Ledaga® is recognized to have a good efficacy profile with a confirmed treatment response achieved in 76.7% of the efficacy evaluable population in the pivotal trial (Lessin S.R. et al JAMA Dermatol. 2013; 149(1): 25-32). Marcelo Conti, Laboratorio Varifarma Director, commented: “It is with great pride and responsibility that we take the license of an innovative product like Ledaga®, from Recordati, in South America. We are anxious to work with a company that shares our principles and work ethic as it aims for great results with a patient-centered approach” About Ledaga® Ledaga® gel is an alkylating drug indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients. Ledaga® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Ledaga® gel is commercialized in the EU since June 2019. Ledaga® is a product licensed to Recordati Rare Diseases by Helsinn Healthcare SA,
Switzerland.
For additional information please see the EU Summary of Product Characteristics.
About Varifarma Focused on complex therapies and orphan diseases, Varifarma is a company which is devoted to increasing the life expectancy of the patient. Our continuous commitment is with innovation and the search of new effective therapies what has placed us as market reference in the oncology, hematology, hemophilia, transplant and rare diseases divisions. We are renowned for our product’s high quality and our sustained commitment with the medical and scientific community. For over two decades, we have counted on distinguished professionals who have actively contributed to the search for the best solutions for patients, as well as for new challenges. Our mission inspires a strategy focused on moving towards new therapies, consolidating a portfolio of cutting-edge medications.
About Recordati AG, Rare Diseases branch Recordati AG, Rare Diseases branch is a pharmaceutical company committed to providing often overlooked orphan therapies to the underserved rare disease communities in the world. Recordati Rare Diseases is a part of the Recordati Group, a public international specialty pharmaceutical company committed to the research and development of new specialties with a focus on treatments for rare diseases. Recordati Rare Diseases’ mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases. The company’s headquarters are located in Basel, Switzerland, with Recordati’s corporate headquarter offices located in Milan, Italy.
2
For more information:
Varifarma Luciana Conti Group Head of Communication Buenos Aires, Argentina Tel: +54 4723-2830 lconti@varifarma.com.ar For more information, please visit www.varifarma.com and follow us on: Facebook:
h ps://www.facebook.com/LaboratorioVarifarma
Linkedin:
h ps://www.linkedin.com/company/laboratorio-varifarma
Twitter:
h ps://twi er.com/varifarma
Recordati AG, Rare Diseases branch Bruno Parenti Head of APAC, LATAM and CIS Region +41 79 469 37 13 parenti.b@recordati .com For more info visit www.recordatirarediseases.com
tt
tt
tt
tt
3